JP2013538825A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538825A5
JP2013538825A5 JP2013530177A JP2013530177A JP2013538825A5 JP 2013538825 A5 JP2013538825 A5 JP 2013538825A5 JP 2013530177 A JP2013530177 A JP 2013530177A JP 2013530177 A JP2013530177 A JP 2013530177A JP 2013538825 A5 JP2013538825 A5 JP 2013538825A5
Authority
JP
Japan
Prior art keywords
methyl
cancer
hydrogen
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530177A
Other languages
English (en)
Japanese (ja)
Other versions
JP5956448B2 (ja
JP2013538825A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051163 external-priority patent/WO2012039972A1/en
Publication of JP2013538825A publication Critical patent/JP2013538825A/ja
Publication of JP2013538825A5 publication Critical patent/JP2013538825A5/ja
Application granted granted Critical
Publication of JP5956448B2 publication Critical patent/JP5956448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530177A 2010-09-21 2011-09-12 医薬組成物 Active JP5956448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38478110P 2010-09-21 2010-09-21
US61/384,781 2010-09-21
PCT/US2011/051163 WO2012039972A1 (en) 2010-09-21 2011-09-12 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2013538825A JP2013538825A (ja) 2013-10-17
JP2013538825A5 true JP2013538825A5 (enExample) 2014-10-30
JP5956448B2 JP5956448B2 (ja) 2016-07-27

Family

ID=44674894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530177A Active JP5956448B2 (ja) 2010-09-21 2011-09-12 医薬組成物

Country Status (31)

Country Link
US (2) US8686018B2 (enExample)
EP (2) EP2619182B1 (enExample)
JP (1) JP5956448B2 (enExample)
KR (1) KR101911105B1 (enExample)
CN (1) CN103097358B (enExample)
AU (1) AU2011305872B2 (enExample)
BR (1) BR112013002484B1 (enExample)
CA (1) CA2806121C (enExample)
CL (1) CL2013000675A1 (enExample)
CY (1) CY1118680T1 (enExample)
DK (1) DK2619182T3 (enExample)
ES (1) ES2610185T3 (enExample)
HR (1) HRP20170042T1 (enExample)
HU (1) HUE031408T2 (enExample)
IL (1) IL224288A (enExample)
LT (1) LT2619182T (enExample)
ME (1) ME02575B (enExample)
MX (1) MX2013003162A (enExample)
MY (1) MY162146A (enExample)
NZ (1) NZ606629A (enExample)
PE (1) PE20131343A1 (enExample)
PH (1) PH12013500467A1 (enExample)
PL (1) PL2619182T3 (enExample)
PT (1) PT2619182T (enExample)
RS (1) RS55566B1 (enExample)
RU (1) RU2606510C2 (enExample)
SG (1) SG188188A1 (enExample)
SI (1) SI2619182T1 (enExample)
SM (2) SMT201700008T1 (enExample)
UA (1) UA113499C2 (enExample)
WO (1) WO2012039972A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
CN105431416B (zh) 2013-06-12 2019-01-08 科研制药株式会社 4-炔基咪唑衍生物和含有其作为有效成分的药物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
SG11201609770TA (en) * 2014-05-23 2016-12-29 Eisai R&D Man Co Ltd Combination therapies for the treatment of cancer
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
JP6689297B2 (ja) 2015-07-23 2020-04-28 武田薬品工業株式会社 複素環化合物
CA3002144C (en) 2015-10-16 2024-01-23 Eisai R&D Management Co., Ltd. Ep4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
US20200352906A1 (en) * 2018-02-05 2020-11-12 Shenzhen Ionova Life Science Co., Ltd. Heterobicyclic Carboxylic Acids for Treating Cancer or Inflammatory Diseases
IL296007B2 (en) * 2020-03-04 2026-03-01 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Synthesis of a novel EP4 antibody and use for cancer and inflammation
WO2022037601A1 (zh) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
TWI877433B (zh) 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療pik3ca突變癌症的組合療法
CN114790176B (zh) * 2021-01-25 2026-07-17 武汉人福创新药物研发中心有限公司 咪唑类化合物及其制备方法和用途
TWI916497B (zh) 2021-01-28 2026-03-01 大陸商深圳眾格生物科技有限公司 咪唑醯胺衍生物及其藥物組合物、製備方法和應用
CA3230557A1 (en) * 2021-09-03 2023-03-09 Xuejun Zhang Ep4 antagonist compound as well as salt, polymorph, and use thereof
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
KR20240124927A (ko) 2021-12-23 2024-08-19 에자이 알앤드디 매니지먼트 가부시키가이샤 Ep4 길항제의 결정질 염 형태
US20250381143A1 (en) * 2021-12-30 2025-12-18 Adlai Nortye Biopharma Co., Ltd. A solid pharmaceutical composition
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0421671A (ja) * 1990-05-16 1992-01-24 Mitsubishi Kasei Corp 4―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
CA2536870C (en) 2003-09-03 2009-10-27 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
WO2005070889A1 (en) 2004-01-23 2005-08-04 E.I. Dupont De Nemours And Company Herbicidal amides
AU2005238291A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
KR20070006890A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1891048A1 (en) * 2005-06-11 2008-02-27 Vernalis (R&D) Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
CN102659659B (zh) 2005-11-21 2014-07-23 盐野义制药株式会社 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物
RU2395499C2 (ru) * 2006-02-06 2010-07-27 Тайсо Фармасьютикал Ко., Лтд. Ингибитор связывания сфингозин-1-фосфата
CA2654811A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
AU2007283404B2 (en) 2006-08-11 2013-04-18 Merck Canada Inc. Thiophenecarboxamide derivatives as EP4 receptor ligands
JP5069752B2 (ja) 2006-12-15 2012-11-07 グラクソ グループ リミテッド Ep4受容体アゴニストとしてのベンズアミド誘導体
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
US7560936B1 (en) 2007-04-24 2009-07-14 Integrated Device Technology, Inc. Method and apparatus for ground bounce and power supply bounce detection
AU2008263883B2 (en) 2007-06-15 2014-03-13 Basf Se Method for producing difluoromethyl-substituted pyrazole compounds
EP2172447A4 (en) * 2007-07-03 2011-08-24 Astellas Pharma Inc amide
CN101711245B (zh) 2007-07-19 2015-03-25 H.隆德贝克有限公司 5元杂环酰胺及相关的化合物
CL2008002241A1 (es) 2007-07-31 2009-12-28 Bayer Cropscience Sa Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
JP5411927B2 (ja) * 2008-05-06 2014-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1アンタゴニストとしてのピラゾール化合物
ES2518919T3 (es) 2008-05-14 2014-11-05 Astellas Pharma Inc. Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética
EP2310360B1 (en) 2008-08-01 2012-08-29 Bayer CropScience AG Fungicide n-cycloalkyl-n-biphenylmethyl-carboxamide derivatives
CN102149384B (zh) * 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
MX2011003166A (es) 2008-09-25 2011-04-27 Merck Frosst Canada Ltd Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.

Similar Documents

Publication Publication Date Title
RU2013118209A (ru) Фармацевтическая композиция
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
JP2010001302A5 (enExample)
JP2011528658A5 (enExample)
JP2014513704A5 (enExample)
JP2011518833A5 (enExample)
JP2014508811A5 (enExample)
HRP20161074T1 (hr) Benzoksazolski inhibitori kinaza i postupci njihove upotrebe
JP2014527042A5 (enExample)
IN2014MN02106A (enExample)
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
RU2016150650A (ru) Комбинированная терапия для лечения рака
JP2015529234A5 (enExample)
JP2013525444A5 (enExample)
JP2011505356A5 (enExample)
JP2013520431A5 (enExample)
JP2018502824A5 (enExample)
JP2012504560A5 (enExample)
JP2014509653A5 (enExample)
NZ600982A (en) Antineoplastic combinations containing hki-272 and vinorelbine
JP2012509265A5 (enExample)
JP2016530242A5 (enExample)
JP2010521516A5 (enExample)
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
TW200900388A (en) Antiparasitic agents